MicroRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 9, 2013, Pages 1156-1162

  Cazzoli, Riccardo ^a,b   Buttitta, Fiamma ^a   Di Nicola, Marta ^a   Malatesta, Sara ^a   Marchetti, Antonio ^a   Rom, William N ^b   Pass, Harvey I ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diagnostic test; Exosome; Lung adenocarcinoma; microRNA; Screening test

Indexed keywords

MICRORNA; MICRORNA 100; MICRORNA 139; MICRORNA 154; MICRORNA 200B; MICRORNA 378A; MICRORNA 379; MICRORNA 629; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; DISEASE MARKER; EXOSOME; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOMA; LUNG GRANULOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RNA STABILITY; SMOKING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; EXOSOMES; FEMALE; FOLLOW-UP STUDIES; GRANULOMA; HUMANS; LUNG NEOPLASMS; MALE; MASS SCREENING; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84883373154     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318299ac32     Document Type: Article

References (37)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-236.
2. The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
3. Zomer A, Vendrig T, Hopmans ES, van Eijndhoven M, Middeldorp JM, Pegtel DM. Exosomes: fit to deliver small RNA. Commun Integr Biol 2010;3:447-450.
4. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008;105:10513-10518.
5. Cortez MA, Calin GA. MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009;9:703-711.
6. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009;60:167-179.
7. Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 2011;91:579-587.
8. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsamiR-205 expression distinguishes squamous from nonsquamous nonsmall-cell lung carcinoma. J Clin Oncol 2009;27:2030-2037.
9. Boeri M, Verri C, Conte D, et al. MicroRNA signatures in tissues and plasma predict development and prognosis of CT detected lung cancer. Proc Natl Acad Sci USA 2011;108(9):3713-3718.
10. Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol 2011;4:575-586.
11. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654-659.
12. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008;18:997-1006.
13. Yang C, Robbins PD. The roles of tumor-derived exosomes in cancer pathogenesis. Clin Dev Immunol 2011;2011:842849.
14. Juan W, Wen G, Cheng-Jun Z, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 2011;30(6):407-414.
15. Jensen J, ∅rntoft T. Normalization of real-time quantitative RT-PCR data: a model based variance estimation approach to identify genes suited for normalization-applied to bladder-and colon-cancer data-sets. Cancer Research 2004;(64):5245-5250.
16. Witten IH, Frank E. Data Mining: Practical Machine Learning Tools and Techniques, 2nd Ed. San Francisco, CA: Morgan Kaufmann, 2005.
17. Lodes MJ, Caraballo M, Suciu D, et al. Detection of cancer with Serum microRNAs on an Oligonucleotide Microarray. PLoS One 2009;4(7):e6229.
18. National Cancer Institute. Statistical tools and data (Cancer.gov web site). May, 2011. Available at: http://www.cancer.gov/statistics. Accessed may 5, 2011.
19. Heisey R, Clemons M, Granek L, et al. Health care strategies to promote earlier presentation of symptomatic breast cancer: perspectives of women and family physicians. Curr Oncol 2011;18:e227-e237.
20. Majek O, Danes J, Skovajsova M, et al. Breast cancer screening in the Czech Republic: time trends in performance indicators during the first seven years of the organised programme. BMC Public Health 2011;11:288.
21. Arolfo S, Teggia PM, Nano M. Gastrointestinal stromal tumors: thirty years experience of an institution. World J Gastroenterol 2011;17: 1836-1839.
22. Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH. Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer 2009;10:42-46.
23. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB. Computed tomography screening and lung cancer outcomes. JAMA 2007;297:953-961.
24. Pastorino U. Lung cancer screening. Br J Cancer 2010;102:1681-1686.
25. Davalos V, Esteller M. MicroRNAs and cancer epigenetics: a macrorevolution. Curr Opin Oncol 2010;22:35-45.
26. Patnaik SK, Kannisto E, Knudsen S, Yendamuri S. Evaluation of microRNA expression profiles that may predict recurrence of localized stage I non-small cell lung cancer after surgical resection. Cancer Res 2010;70:36-45.
27. Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A, Yakhini Z. Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One 2009;4:e8003.
28. Gao W, Shen H, Liu L, Xu J, Xu J, Shu Y. MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin Oncol 2011;137:557-566.
29. Eichner LJ, Perry MC, Dufour CR, et al. miR-378 mediates metabolic shift in breast cancer cells via the PGC-1/ERR transcriptional pathway. Cell Metab 2010;12:352-361.
30. Kumarswamy R, Mudduluru G, Ceppi P, et al. MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer 2012;130:2044-2053.
31. Fridman E, Dotan Z, Barshack I, et al. Accurate molecular classification of renal tumors using microRNA expression. J Mol Diagn 2010;12:687-696.
32. Chang KH, Miller N, Kheirelseid EA, et al. MicroRNA signature analysis in colorectal cancer: identification of expression profiles in stage II tumors associated with aggressive disease. Int J Colorectal Dis 2011;26:1415-1422.
33. Ding J, Huang S, Wu S, et al. Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA. Nat Cell Biol 2010;12:390-399.
34. Niemoeller OM, Niyazi M, Corradini S, et al. MicroRNA expression profiles in human cancer cells after ionizing radiation. Radiat Oncol 2011;6:29.
35. Wang W, Peng B, Wang D, et al. Human tumor microRNA signatures derived from large-scale oligonucleotide microarray datasets. Int J Cancer 2011;129:1624-1634.
36. Haenisch S, Laechelt S, Bruckmueller H, et al. Down-regulation of ATP-binding cassette C2 protein expression in HepG2 cells after rifampicin treatment is mediated by microRNA-379. Mol Pharmacol 2011;80:314-320.
37. Guo L, Liu Y, Bai Y, Sun Y, Xiao F, Guo Y. Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer 2010;46:1692-1702.